New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
07:22 EDTGILDGilead's single tablet Stribild shows positive results in two HIV studies
Gilead announced two-year results from two pivotal Phase 3 studies evaluating the company’s newest single tablet HIV regimen, StribildTM, among treatment-naïve patients with HIV-1 infection. Data show that Stribild was non-inferior after two years of treatment to two standard of care HIV regimens, Atripla in Study 102 and a protease-based regimen of ritonavir-boosted atazanavir plus Truvada in Study 103. The regimen was approved by the FDA on August 27 for use by treatment-naïve HIV-positive adults based on 48-week results from Studies 102 and 103. A marketing application for Stribild is currently under review in the European Union.
News For GILD From The Last 14 Days
Check below for free stories on GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent GILD news | >>
September 5, 2014
09:50 EDTGILDGilead down 3.5% after reports of potential generic Sovaldi deal coming
09:49 EDTGILDGilead near deal for generic Sovaldi for developing countries, Bloomberg reports
Subscribe for More Information
09:43 EDTGILDGilead drops 6%, or $6.41, to $100.45
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA YHOO WFM SLW ABX GOOG FB BIDU
September 4, 2014
11:30 EDTGILDStocks with call strike movement; AAL GILD
American Airlines (AAL) November 44 call option implied volatility increased 6% to 39, Gilead (GILD) November 130 call option implied volatility decreased 5% to 40 according to IVolatility.
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
07:21 EDTGILDMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
September 3, 2014
16:01 EDTGILDOptions Update; September 3, 2014
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA TWTR PBR C GILD NFLX FB BIDU
05:51 EDTGILDStocks with implied volatility movement; GILD XLE
Stocks with implied volatility movement; Gilead (GILD) 36, Energy Select Sector SPDR (XLE) 14 according to iVolatility.
September 2, 2014
16:00 EDTGILDOptions Update; September 2, 2014
Subscribe for More Information
09:41 EDTGILDActive equity options trading on open
Subscribe for More Information
<< 1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use